XML 58 R21.htm IDEA: XBRL DOCUMENT
v2.4.0.8

3. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables) | 9 Months Ended
--- | ---
Dec. 31, 2013
Accounting Policies [Abstract] |
Sumarry of cash balances |
Aethlon Medical, Inc. |  | $ | 588,066 |
Exosome Sciences, Inc. |  |  | 1,266,875 |
Consolidated Cash Balance |  | $ | 1,854,941 |
Research and development expenses |
|  | December 31, |  |  | December 31, |
|  | 2013 |  |  | 2012 |
Three months ended |  | $ | 542,383 |  |  | $ | 371,253 |
Nine months ended |  | $ | 1,178,488 |  |  | $ | 1,034,335 |

X
- Definition Research and development expenses + References No definition available. + Details
Name: | aemd_ResearchAndDevelopmentExpensesTableTextBlock
Namespace Prefix: | aemd_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | us-gaap_AccountingPoliciesAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of the components of cash and cash equivalents. + References No definition available. + Details
Name: | us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration